Cutler Group’s Intellia Therapeutics NTLA Stock Holding History
Bought
Maintained
Sold
Other funds holding NTLA
AIM
DTC
NAMA
Cutler Group's NTLA Position: Q1 2024 in Review
Cutler Group sold out of Intellia Therapeutics (NTLA) in Q1 2024, closing a stake of 200 shares — an estimated $6K sold.
Cutler Group first reported a position in NTLA in Q2 2017 and held it in 16 quarters. The position peaked at $1.49M in Q2 2021. 284 funds tracked by Wall St. Rank hold NTLA as of Q1 2024.
- Cutler Group reported no remaining Intellia Therapeutics position as of Q1 2024 after selling out during the quarter.
- Cutler Group sold 200 Intellia Therapeutics shares in Q1 2024, an estimated $6K.
- Cutler Group first reported a position in Intellia Therapeutics in Q2 2017 and held it in 16 quarters.
- Cutler Group's Intellia Therapeutics position peaked at $1.49M in Q2 2021.
- 284 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2024.
Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.